Form 4: Kura Oncology Director Diane Parks Receives Stock Options

Director Diane Parks was granted 35,000 stock options in Kura Oncology, Inc. with an exercise price of $8.77.

Summary

• Director Diane Parks acquired 35,000 options to purchase common stock in Kura Oncology, Inc.
• The options have an exercise price of $8.77 per share.
• The grant date for these options is June 4, 2026.
• The options are scheduled to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock.
• Performance risks associated with the company's oncology pipeline.

Future Outlook

The options vest in full on the one-year anniversary of the grant date, June 4, 2027.

Management Comments

• The transaction is a standard equity grant for a director, as indicated by the filing of Form 4.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure long-term commitment to clinical development milestones.

Comparison to Industry Standards

• The grant of 35,000 options is consistent with typical director compensation packages for mid-cap biotechnology firms.
• Vesting schedules of one year are common for non-employee director equity awards in the industry.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of the 35,000 options on June 4, 2027.

Key Dates

Keywords

Kura Oncology, KURA, Director Compensation, Stock Options, Insider Transaction, SEC Form 4